semaglutide and pre-existing conditions Long-term kidney outcomes of in obesity cardiovascular disease in the SELECT trial Are GLP-1s HSA/FSA Eligible? A
Description
HPLC purity testing High-Performance Liquid Chromatography remains the gold standard for peptide purity assessment

Regulatory agencies have been tightening their oversight of compounded GLP-1s for more than a year

Prophylactic effect of Withania somnifera on inflammation in a non-autoimmune prone murine model of lupus

By Saturday, Hims agreed it will not sell its Ozempic lookalike pill after all

What microdosing looks like on the plotter Microdosing typically involves using 10-25% of a standard therapeutic dose

The SELECT trial showed that semaglutide 2.4 mg reduced major adverse cardiovascular events by 20% in people with overweight or obesity and established cardiovascular disease
